Feb 18, 2021 / 01:30PM GMT
Ãystein Soug - Targovax ASA - CEO
Ladies and gentlemen, please let me welcome you to our Capital Markets Day, our key opinion leader event and our fourth quarter 2020 presentation. My name is Ãystein Soug, and I'm the CEO of Targovax.
We have a great program for you for the next couple of hours. Today, its main focus is going to be on the ONCOS-102 development program. And we have people in 4 different countries and hopefully, the technicals will work out well.
We'll start with an update on our latest PD-1 refractory melanoma trial in combination with KEYTRUDA. And for that, we have invited our principal investigator from that trial, Dr. Alexander Shoushtari. After Dr. Shoushtari's presentation, our Chief Medical Officer, Magnus Jäderberg, will lay out the plans that we have for further steps in melanoma, namely a trial intended to create data to support registration of ONCOS-102. He will also touch upon the other trials that we are going in the company, and we'll also put it all into context for you.
After a short break, Chief Scientific Officer, Victor
Targovax ASA Corporate Analyst Meeting Transcript
Feb 18, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers